Back

prof. dr. H.G.M. (Harry) Heijerman

Full Professor

  • Department of Pulmonary Diseases

  1. Contact
  2. Research Programs
  3. Research Output

Contact

E

Research Programs

Research Output (53)

Resting energy expenditure in cystic fibrosis patients decreases after lung transplantation, which improves applicability of prediction equations for energy requirement

Hollander-Kraaijeveld F M, van Lanen A S, de Roos N M, van de Graaf E A, Heijerman H G M nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 975-980 6 p.

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Berkers Gitte, van der Meer Renske, van Mourik Peter, Vonk Annelotte M, Kruisselbrink Evelien, Suen Sylvia Wf, Heijerman Harry Gm, Majoor Christof J, Koppelman Gerard H, Roukema Jolt, Janssens Hettie M, de Rijke Yolanda B, Kemper E Marleen, Beekman Jeffrey M, van der Ent Cornelis K, de Jonge Hugo R nov 2020, In: Journal of Cystic Fibrosis. 19 , p. 955-961 7 p.

Effectiveness of pulmonary rehabilitation at high-altitude compared to sea-level in adults with severe refractory asthma

de Nijs S B, Krop E J M, Portengen L, Rijssenbeek-Nouwens L H, de Vries D, Weersink E J M, Heijerman H G M, Heederik D J J, Lammers J W J sep 2020, In: Respiratory Medicine. 171 , p. 106123

Transparency and diversity in cystic fibrosis research - Authors' reply

McCoy Karen S, Heijerman Harry, Taylor-Cousar Jennifer L, Waltz David, Sosnay Patrick R, Ramsey Bonnie W, Rowe Steven, Welter John 29 aug 2020, In: The Lancet. 396 , p. 602

Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation

Burghard M., Berkers G., Ghijsen S., Hollander-Kraaijeveld F. M., de Winter-de Groot K. M., van der Ent C. K., Heijerman H. G.M., Takken T., Hulzebos H. J. jun 2020, In: Pediatric Pulmonology. 55 , p. 1400-1405 6 p.

Does Circadian Rhythm affect the Pharmacokinetics of Once-Daily Tobramycin in Adults with Cystic Fibrosis?

van Maarseveen E M, van der Meer R, Neef C, Heijerman H G M, Touw D J 11 feb 2020, In: Therapeutic Drug Monitoring. 42 , p. 595-599 5 p.

Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV<sub>1</sub> ≥ 90% predicted at baseline

Aalbers B L, de Winter-de Groot K M, Arets H G M, Hofland R W, de Kiviet A C, van Oirschot-van de Ven M M M, Kruijswijk M A, Schotman S, Michel S, van der Ent C K, Heijerman H G M 7 jan 2020, In: Journal of Cystic Fibrosis. 19 , p. 654-658 5 p.

Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations

de Winter-de Groot Karin M, Berkers Gitte, Marck-van der Wilt Rozemarijn E P, van der Meer Renske, Vonk Annelotte, Dekkers Johanna F, Geerdink Margot, Michel Sabine, Kruisselbrink Evelien, Vries Rob, Clevers Hans, Vleggaar Frank P, Elias Sjoerd G, Heijerman Harry G M, van der Ent Cornelis K, Beekman Jeffrey M 14 nov 2019, In: Journal of Cystic Fibrosis. 19 , p. 614-619 6 p.

Home videos of cystic fibrosis patients using tobramycin inhalation powder:Relation of flow and cough

Meerburg Jennifer J, Albasri Mehdi, van der Wiel Els C, Andrinopoulou Eleni-Rosalina, van der Eerden Menno M, Majoor Christof J, Arets Hubertus G M, Heijerman Harry G M, Tiddens Harm A W M nov 2019, In: Pediatric Pulmonology. 54 , p. 1794-1800 7 p.

Prevention of drug-related complications in cystic fibrosis

van der Meer Renske, Touw Daan J, Heijerman Harry G M nov 2019, In: Current Opinion in Pulmonary Medicine. 25 , p. 666-673 8 p.

All Research Output (53)